Your web browser is out of date! We recommend you update your browser to receive the best possible browsing experience.
Download your Brochure
Purchase Now

Our Unrivalled 2017 Speaker Line-up

Take a look at some of the expert speakers signed up for this year's Oncology Market Access & Pricing Conference: Download the full agenda here


Is your company being represented by a speaker?
Email caitlin@eyeforpharma.com for your unique company discount code


Seth Coombs

Seth Coombs

Vice President, Oncology and injectable Products, Sandoz

Read more

Seth joined Novartis in 2004 as a Global Brand Communications Manager supporting the Diovan business. He moved through a number of roles in both Sales and Marketing during his next 12 years with the company. Most recently, Seth has successfully expanded the Oncology portfolio—launching Cyclophosphamide and Levoleucovorin. In addition, last December, he launched a direct integrated delivery network (IDN) sales force stimulating hospital and clinic demand.

Seth assumed the role of Vice President, Oncology & Injectables, in November 2016 where he is responsible for the development, adaptation and implementation of the portfolio strategy for oncology and injectable products at Sandoz. This includes the management of the product life cycle from development, launch and commercialization and through to product discontinuations. Seth received his MBA from Columbia University and his undergraduate degree from the University of Iowa.

Julie Locklear

Julie Locklear

VP & Head – Health economics & Outcomes research, EMD Serono

Read more

Julie C. Locklear is Vice President & Head of Health Economics & Outcomes Research at EMD Serono, Inc., a business of Merck KGaA, Darmstadt, Germany. As VP & Head of US HEOR at EMD Serono, Julie leads an in-house team specializing in strategic value proposition and end-to-end evidence generation, patient-centric real-world evidence, advanced analytics as well as a field HEOR team who interface with payers, IDNs, key opinion leaders and other access opinion leaders to provide evidence-based data across EMD Serono company products. 

Julie is an executive pharmaceutical leader with over 20 years of experience across all phases of development, both on the commercial and research sides of pharmaceutical organizations. She leverages her Executive Masters in Business Administration and Doctorate in Pharmacy to lead a high functioning, high impact team delivering patient-centric value propositions to optimize patient access and improve outcomes in patients with difficult-to-treat diseases leading to longer, healthier and more productive lives. Her years of experience in global and US payer markets provide her with intimate knowledge of the current and evolving payer and market access landscapes in the US and around the globe. She has led the development and execution of several outcomes-based contracts with 3 of the largest national payer organizations in the US. Dr. Locklear is well published, having authored >30 peer-reviewed publications and >60 peer-reviewed abstracts presented at major scientific congresses.

Sally Cowal

Sally Cowal

Senior Vice President, American Cancer Society-

Read more

Ambassador Sally G. Cowal is Senior Vice President, Global Cancer Control, at the American Cancer Society. She leads the Society’s efforts to reduce the global burden of cancer primarily through advocacy for effective tobacco control measures; improvement of access to cancer screening, treatment and pain relief; and collaborations with other cancer control organizations, advocates, and governments.

She served as the U.S. Ambassador to Trinidad and Tobago and as U.S. Deputy Assistant Secretary of State for Latin America and the Caribbean. She was the founding Director for External Relations at the Joint United Nations Programme on HIV/AIDS, the CEO of two non-profit foundations, and the Chief Liaison Officer for Population Services International (PSI). She serves on several academic and foundation boards and is a Member of the Council on Foreign Relations.

She is a member of the 2016-2018 Board of Directors of the Switzerland-based Union for International Cancer Control (UICC).

Kevin Fitzpatrick

Kevin Fitzpatrick

CEO, CancerLinQ, LLC

Read more

Mr. Fitzpatrick joined ASCO in 2015. He previously served as the Executive Vice President and Chief Innovation Officer of the American College of Cardiology (ACC), where he jointly led the organization’s overall financial management and operational and strategic planning. Prior to joining the ACC, Mr. Fitzpatrick was Vice President of Business Development for Lippincott Williams & Wilkins, and Managing Director of The Duke/Hewlett Packard Center for Outcomes Research and Director of the Trauma Research Laboratory at Duke University Medical Center. He received the Smithsonian Institution/Computer World Healthcare Computing Innovation Award in 1996.

Mr. Fitzpatrick was instrumental in the creation and implementation of the Diabetes Collaborative Registry™, the first global, cross-specialty clinical diabetes registry designed to track and improve the quality of diabetes and metabolic care across the primary care and specialty care continuum. In addition, he has been very involved in the growth and development of ACC’s PINNACLE Registry®, cardiology's largest outpatient quality improvement registry, capturing data on coronary artery disease, hypertension, heart failure and atrial fibrillation.

Prior to joining the ACC, Mr. Fitzpatrick was Vice President of Business Development for Lippincott Williams & Wilkins, a publisher of professional health information resources, and Managing Director of The Duke/Hewlett Packard Center for Outcomes Research and Director of the Trauma Research Laboratory at Duke University Medical Center. He is also a 1996 recipient of the Smithsonian Institution/Computer World Healthcare Computing Innovation Award.

Bryon Wornson

Bryon Wornson

Vice President, Oncology Patient&Health Impact, Pfizer

Read more

Bryon Wornson is the Vice-President, Patient and Health Impact for Pfizer Oncology. He is responsible for the creation and execution of evidence generation and pricing strategies to support our Oncology portfolio.

Prior to this role, Bryon was the Vice President Corporate Affairs  Global Innovative Pharma Business.  Bryon served as the single point of accountability for GIP on Public Affairs and Communications strategies and initiatives to shape the operating environment for GIP and support its commercial objectives around the world.

Bryon began his career at Pfizer in 2005 and has assumed positions of increasing responsibility in Public Affairs, starting as a Government Relations Director for Illinois and Wisconsin and subsequently serving as the Midwest Team Leader in the U.S. Public Affairs team. Before joining Pfizer, Bryon worked for the Governor and Speaker in Wisconsin state government and earlier in his career provided public affairs support at Eli Lilly. Bryon received his undergraduate degree in Political Science from the University of Wisconsin-Eau Claire.

Purchase the Post-Conference Materials

Event Presentations • Event Audio • On Demand Subscription

Clorinda Walley

Clorinda Walley

Executive Director, Good Days

Read more

Clorinda Walley leads the charity with more than 20 years of experience in the healthcare industry and over 8 years in strategic philanthropy. She effectively oversees the strategic and operational responsibility for the staff and programs for Good Days, as well as the expansion and execution of its mission. With in-depth knowledge of the organization’s core programs, operations and business plans, Clorinda ensures the organization’s programmatic excellence. With her proven expertise, Clorinda has continuously ensured consistent quality of finance and administration, procurement of donations, internal and external communications and development of all patient care initiatives.

Ariella Evenzahav

Ariella Evenzahav

Former US Market Analytics, Takeda Oncology

Read more

Ariella Evenzahav is head of US Oncology Market Research and Analytics at Takeda. Prior to holding this position, she was an independent consultant, where she partnered with a number of different pharmaceutical companies to help drive commercial strategies of oncology drugs in various phases of development She has years of experience in commercial oncology drug development in various functions. Prior to consulting, Dr. Evenzahav was Director of Commercial Operations, Oncology at Pfizer Inc, where her responsibilities included, among others, ensuring delivery of accurate and actionable commercial development plans and forecasts for the oncology portfolio as well as alignment among teams representing the individual oncology drugs. Dr. Evenzahav oversaw the commercial development of the early oncology pipeline as well as drugs in later development stages for the treatment of malignant melanoma, glioblastoma, breast cancer, and lung cancer. She also completed a number of commercial evaluations for licensing and acquisition opportunities in the oncology space. She was the commercial lead on the hematological tumor strategy team and was responsible for assessing areas of unmet need in the hematologic tumor space and identifying potential candidates from Pfizer's pipeline which might meet those needs. She holds a BS from Brown University and a PhD in Bio-organic Chemistry from Columbia University.

Van Crocker

Van Crocker

President, Outcomes team, Healthagen Aetna

Read more

Van Crocker has a 15+ year career in the healthcare, technology, and management consulting fields. He currently leads the Healthagen Outcomes business unit at Healthagen, an Aetna company. Healthagen Outcomes leverages Aetna’s vast member scale and broad analytical expertise to address the outcomes and development challenges faced by pharmaceutical/ biotech/ device companies worldwide, allowing them vastly improve their R&D efforts and value propositions in an evolving economic environment.

Previously, Mr. Crocker led finance and business development for AuraSense, a biotechnology company founded by world-renowned nanomedicine authority, Dr. Chad Mirkin, and funded by AbbVie Biotech Ventures. The company has developed a broad array of genetic and nanoparticle-based therapeutic and diagnostic platforms, with applications for cancer, cardiovascular disease, autoimmune conditions and Alzheimer’s, among others.

Prior to AuraSense, Mr. Crocker was a management consultant with Booz & Company’s Global Healthcare Practice, focusing on payer/ provider/ pharmacy clients. Prior to Booz, Mr. Crocker helped to launch NanoInk, Inc., a nanotechnology firm founded in 1999. Mr. Crocker began his career at Oracle Corporation.

Mr. Crocker earned an MBA with honors from the Kellogg School of Management. He received his Bachelor of Science degree in Commerce from the University of Virginia.

Dr. Joanne Buzaglo

Dr. Joanne Buzaglo

SVP, Research & Training, Cancer Support Community

Read more

Joanne Buzaglo, PhD, is the Senior Vice President of Research & Training at the Cancer Support Community. She leads strategic initiatives that leverage the research capabilities of CSC’s global cancer patient support network through collaborations with patients, caregivers, advocacy organizations, academics, health economists and leaders in industry. One such initiative is the Cancer Experience Registry, an online vehicle that engages patients and caregivers to inform future priorities in research, innovative programs and health care policy.

Dr. Buzaglo is a behavioral health researcher and clinical psychologist with extensive experience in the development and evaluation of theoretically guided interventions designed to help patients cope with the complex challenges associated with cancer. Before arriving at CSC, she was the Deputy Director of the Fox Chase Cancer Center’s NCI-funded Behavioral Research Core Facility, whose mission is to provide consultation and training in behavioral principles relating to research design, program evaluation, and tailored communications. She is a Co-Investigator on a number of PCORI initiatives and has been a Co- Investigator on numerous NCI- and DoD-funded cancer-related studies that focus on enhancing doctor-patient communication, clinical trial participation, patient adherence to medical recommendations, and adaptation to cancer survivorship. She received her doctorate at Temple University and completed a post-graduate fellowship in Health Services, Research, & Development at the VA Medical Center in Philadelphia, PA. In addition, she trained at the Center for Cognitive Therapy at the University of Pennsylvania and at Friends Hospital of Philadelphia. Dr. Buzaglo joined Cancer Support Community in August 2008.

Purchase the Post-Conference Materials

Event Presentations • Event Audio • On Demand Subscription

Matthew Monberg

Matthew Monberg

Director, Outcomes Research Immuno-Oncology / PD-1, Merck

Read more

Matthew Monberg is a Director and Value Evidence Lead within the Center for Observational and Real-world Evidence (known as CORE) at Merck & Company. His work supports reimbursement-related evidentiary needs in immuno-oncology across US and global markets. This includes conducting outcomes research, informing clinical trial design, developing economic models, and training a field-based health systems team. He has led multiple parallel scientific advice consultations with the European Medicines Agency (EMA) and health technology assessment (HTA) organizations. He also led Merck’s engagement with the Institute for Clinical and Economic Review (ICER) during its multi-technology assessment in lung cancer.

Prior to joining Merck, he worked for GlaxoSmithKline and Eli Lilly & Company. In his 17 years within industry, he has supported several product launches in oncology and other therapeutic areas. He has led value-based pricing initiatives relating to oncology and hematology products. In addition to health outcomes roles, he has worked within medical affairs and medical education organizations. He received his PhD from the University of Illinois at Chicago in Epidemiology, has a Master of Science degree from the University of the Sciences in Philadelphia (where he also serves as adjunct faculty), and a Bachelor of Science degree from the University of Notre Dame.

Adrian Charbin

Adrian Charbin

Director, Global Payer Insights & Access: Immunoncology, Pfizer

Read more

Adrian is a Director, Payer Insights and Access, at Pfizer where he works as part of their immuno-oncology team. Most recently, Adrian has led market access launch readiness for BAVENCIO (avelumab) across multi-disciplinary teams including policy, communications and medical. In addition, he has a keen interest in the development of innovative contracting strategies in the US. Prior to joining the IO/Avelumab team, Adrian worked at QuintilesIMS where he worked across a large range of projects in market access, valuations and due diligence. Adrian has a PhD in Biochemistry from University College London, where he was a Boehringer Ingelheim Fonds Fellow, and a BA in Natural Sciences from Cambridge University.

Bill Goodson

Bill Goodson

Director, Market Access & Reimbursement, Eisai Inc.

Read more

Responsible for the development, implementation, monitoring, and compliance of hub operations and patient assitance programs across the EISAI Portfolio to build reimbursement confidence, secure provider reimbursement, remove barriers and ensure patient access to EISAI's products.

Jerry Conway

Jerry Conway

Vice President of payer relations and Reimbursement, Foundation Medicine

Read more

Jerry Conway, Vice President of Payer Relations & Reimbursement, joined Foundation Medicine Inc. in May 2012 with over 22 years of sales and executive management experience in the routine clinical and esoteric laboratory marketplaces working first in physician sales and marketing, then later with national and regional payers on contracting, education and utilization management initiatives involving laboratory services. His experience includes payer contracting and reimbursement in a wide range of business environments including Fortune 500 and start-up companies. In 2011, Jerry joined Metamark Genetics Inc., a national provider of cancer prognostic tests and services, as Vice President of Reimbursement & Payer Contracting. At Metamark, Jerry was responsible for payer strategy development for several assays in the pre-launch phase. In 1997, Jerry joined Genzyme Genetics, a national provider of genetic health services, to develop business relationships and contracts with regional and national payers based in the Northeastern United States. In 2001, he was promoted to the role of Director of National Accounts with Genzyme Genetics and was responsible for business development and contracts with national and cross-regional payers. In 2004, Jerry was promoted to Vice President of Managed Care where he oversaw a staff of 11 regional and national account directors who were focused on payer account management, contracting, pull through, education and care management programming. With a particular focus on reimbursement for routine and novel genetic tests and services in the reproductive and oncology markets at Genzyme Genetics, Jerry has a demonstrated track record of increased revenue and profitability. Under his leadership in payer contracting and reimbursement over 14 years, Jerry helped to favorably position the company for a recent $975 million acquisition by Laboratory Corporation of America® Holdings on December 1, 2010.

Kendall Millar

Kendall Miller

Clinical Product Manager - Oncology, ARUP Laboratories

Read more

Ms. Miller has been with ARUP for more than thirteen years, ten of which she spent in the laboratory  performing , developing, and validating therapeutic drug-monitoring assays. She has several years’ clinical product management experience in anatomic pathology, molecular oncology, and hematopathology, and has published in the field of therapeutic drug monitoring. Ms. Miller currently serves as a liaison between the laboratory and business development, providing market research and analysis to broaden ARUP’s test offerings. She holds a bachelor of science in microbiology, with a chemistry minor, from Brigham Young University, and is certified by the American Society for Clinical Pathology (ASCP) in chemistry.

Purchase the Post-Conference Materials

Event Presentations • Event Audio • On Demand Subscription

Andrea Lorance

Andrea Lorance

Clinical Product Manager - Genetics, ARUP Laboratories

Read more

As the clinical product manager for Genetics at ARUP, Ms. Lorance analyzes genetic testing trends, facilitates bringing new tests to market, and explores opportunities for expanding ARUP’s genetic testing menu. Ms. Lorance spent eight years in the Chemistry and Molecular Genetics departments at ARUP, where she validated the first molecular newborn screen for the state of Utah. She holds a bachelor of science in cellular and molecular biology, with a chemistry minor, from Fort Lewis College in Colorado, and is certified by the American Society for Clinical Pathology (ASCP) in chemistry and molecular biology.

Anita Dopkosky

Anita Dopkosky

Director National Accounts, Walgreens

Read more

Anita Dopkosky serves as a Director of National Accounts responsible for account management and business development with pharma and biotech partners. In this position, she monitors the FDA pipeline of new products for specialty disease states to identify the unique needs of these products and determine how to best service the patients who receive them. Prior to her role in account management, she was the Manager of Special Programs at Walgreens Specialty. Before joining Walgreens she served as the Pharmacist in Charge (PIC) at McKesson Specialty. Anita earned a B.S. in pharmacy from Duquesne University and a Master of Administrative Sciences from The Johns Hopkins University.

Mridula Iyer

Mridula Iyer

Director Companion Diagnostics, Quest Diagnostics

Read more

Mridula Iyer, Ph.D., currently serves as the General Manager, Precision Medicine at Quest Diagnostics leading the Precision Medicine business for all therapeutic areas.

Dr. Iyer’s professional experience spans the academic Pharma and biotechnology industry.

At Quest Diagnostics, she is responsible for providing strategic direction to the Precision Medicine/Companion Dx business, working closely with other teams to align with the market needs. Prior to joining Quest Diagnostics, Dr Iyer was at AZ as Director Diagnostics, at Molecular Health as Director of Product Marketing and with Qiagen Inc. leading their North American Molecular Diagnostics marketing and Global Product Management teams.

Bob Orzechowski

Bob Orzechowski

Chief Operating Officer, Lancaster Cancer Centre

Read more

Bob has worked in all aspects of medical practice management for various private groups, including Chief Operating Officer for private hematology & medical oncology practices. Currently, he is COO for Lancaster Cancer Center, Ltd. He authored numerous articles and presented to audiences nationally on business, HR, and medical management topics. Bob is the founder and Past President of both state and national hematology-oncology management organizations. Bob was also an Adjunct Instructor at local colleges for over 20 years, teaching business, management and HR college credit courses.

He received his BS from The Pennsylvania State University, and his MBA from Fairleigh Dickinson University. Bob is a certified Senior Professional in Human Resources (SPHR and SHRM-SCP). He is a decorated combat veteran, having served three tours of duty in Vietnam with the U.S. Marine Corps, after which he received an Honorable discharge.

Burt Zweigenhaft

Burt Zweigenhaft

Former President, National Association of Specialty Pharmacy

Read more

Mr. Zweigenhaft is key industry thought leader and accomplished executive in the specialty-biotech pharmaceutical and oncology cancer care ecosystems.

Mr. Zweigenhaft is the Managing Partner of Upstream-Partners, LLC. a New York based Private Equity Company focused on incubating new healthcare delivery services, specialty bio-pharmaceuticals, genomics, precision medicine and health technologies into healthcare ecosystems. Mr. Zweigenhaft guidance has supported several key drug launch market strategies with industry leaders the likes of Genzyme, Pharmacyclics, Gilead, Janssen, Pfizer, Alexion, Bayer, GSK, Seattle Genetics, Monogram Science, Roche, Genentech, CureVax and Genomic Health.

Today Mr. Zweigenhaft is Past President and Executive Board member of the National Association of Specialty Pharmacy (NASP), representing the industry on National Policy, Specialty Pharmacy Education and Government Relations based in Washington, DC. Additionally Mr. Zweigenhaft is consultant and senior advisor to the shareholder group of Cancer Treatment Centers of America.

Previously Mr. Zweigenhaft held the office of CEO and Vice Chairman and Founder of Onco360 a national oncology pharmacy care management provider with corporate offices in New York City. The Onco360 model provided the full continuum of oncology pharmacy service solutions to over 3,000 community based Hematologists and Oncologists, Hospital Based Cancer Centers of Excellence in coordination with managed care providers insuring over 45 million people. Under Burt’s vision and leadership Onco360 created, developed and implemented the industry best practice oncology pharmacy model by incorporating the strengths of Board Certified Oncology Pharmacists and Oncology Patient Advocates to support the prospective and concurrent patient centered oncology medical home model. In 2014 PharMerica acquired controlling interest in Onco360 and relocated the company in 2015 to Louisville, KY.

Mr. Zweigenhaft previously served as Senior Vice President of Managed Care Sales and Marketing, Government Programs, Trade Relations and Business Development Strategies for Priority Healthcare Corporation, a publicly traded company in the specialty pharmacy sector with $2.3 billion in specialty drug revenues before being acquired by Express Scripts in 2005.

Prior to 2002, Mr. Zweigenhaft spent several years serving as a specialty pharmacy consultant to Medco, CuraScript, BioScrip and several Regional National Blue Cross Blue Shield and National Managed Care Payer programs.

Mr. Zweigenhaft holds a Bachelor of Science in Management and Economics from the University of Buffalo School of Management, where he also serves on the Dean’s Advisory Committee and remains active with the University of Buffalo schools of Pharmacy and Medicine including the Center of Excellence for Bioinformatics and Health Sciences. Mr. Zweigenhaft is a member of AMCP (American Managed Care Pharmacy), HOPA (Hematology Oncology Pharmacists Association) and ASCO (American Society of Consulting Oncologists). Mr. Zweigenhaft also serves on the Editorial Boards of several industry publications and is Editor and Chief of the Journal for Value Based Cancer Care. Mr. Zweigenhaft is also Co-Chairman and Co-Founder of the AVBCC (Association for Value Based Cancer Care) and serves as a Board Member of and President of NASP (National Association of Specialty Pharmacy) in Washington, DC.

Philanthropically Mr. Zweigenhaft serves on the National Board of Swim Across America for Cancer; a NFP organization that has raised $90 million to date to support cancer research laboratories. In 2015 Mr. Zweigenhaft was honored to be the recipient of the CancerCare “Help and Hope Award”.

Purchase the Post-Conference Materials

Event Presentations • Event Audio • On Demand Subscription

Amanda Bruno

Amanda Bruno

Senior Director, Value Evidence Leader, Cross Therapy Area, GSK

Read more

Dr. Bruno has 15 years experience in healthcare and is currently a Value Evidence & Outcomes leader at GlaxoSmithKline. In this role, Dr. Bruno and her team provide support for GSK Oncology, Infectious Diseases and Dermatology medicines in development. Prior to this, she led the US Specialty (cardiovascular [CV], virology & immunology) health economics & outcomes research (HEOR) team at Bristol-Myers Squibb. Before joining industry, Dr. Bruno was a Senior Director in HEOR Scientific Consulting at Xcenda. In this role, she specialized in global health economics, real-world evidence, outcomes research, and market intelligence to demonstrate product value and drive market access. Before joining Xcenda, Dr. Bruno was responsible for leading a research team in Los Angeles for a consultancy that is now part of IMS Health. In this role, she led research activities with life sciences and managed care, including the development, implementation, and evaluation of quality-based provider incentive programs among regional payers in the U.S. Also, as a Research Fellow for the Centers for Disease Control and Prevention, Dr. Bruno worked with the Prevention Effectiveness Branch publishing recommendations for effective community-based interventions and programs based on economic evidence.

Dr. Bruno’s experience ranges across several disease areas and she has authored a variety of scientific publications appearing in Health Services Research, Medical Care, Radiology, AIDS Care, Journal of Oncology Practice, American Health & Drug Benefits, and the Journal of Urology, among others. Dr. Bruno received her PhD in Health Services with a cognate in Pharmacoeconomics from UCLA where she was a recipient of the UCLA/RAND Health Services Research Training Grant supported by the Agency for Health Care Research Quality. Her MPH in Health Policy and Management was completed at Emory University and her Bachelor of Science at Tulane University.

James Harnett

James Harnett

Senior Director, Analytical Sciences Lead, Pfizer

Read more

Dr. James Harnett is a Senior Director in Real World Data and Analytics (RWDnA) for Pfizer’s Patient and Health Impact organization. Dr. Harnett supported establishing the RWDnA function at Pfizer that drives collaboration and the timely development and delivery of tools, solutions and capabilities for the use of real world data and advanced analytics across the enterprise. Prior to his current position, Dr. Harnett was a Team Leader in Health Economics & Outcomes Research overseeing research programs across numerous therapeutic areas as well as establishing groundbreaking collaborations with payers and other healthcare stakeholders on joint research initiatives and long-term integrated health partnerships.

Dr. Harnett has worked with Pfizer for over 15 years creating and leading research programs in support of development and in-line products across therapeutic franchises including oncology, vaccines, inflammation and immunology, pain, women’s health, neurology, psychiatry, diabetes, urology, respiratory, and anti-infectives. He has extensive experience in working with US customers and supporting Global reimbursement and regulatory submissions. Dr. Harnett has authored over 30 peer-reviewed publications.

Dr. Harnett received his Bachelor of Science in Pharmacy and Doctor of Pharmacy degrees at Rutgers, The State University of New Jersey. He received a Master of Science degree in Clinical Epidemiology and Health Services Research at Weill Cornell Graduate School of Medical Sciences. Dr. Harnett completed a specialized pharmacy residency in Drug Information Practice at Robert Wood Johnson University Hospital and was adjunct faculty at Rutgers College of Pharmacy.

Andrew Schorr

Andrew Schorr

Founder, Patient Power

Read more

Andrew Schorr of Seattle is a medical journalist who was diagnosed with chronic lymphocytic leukemia in 1996. By participating in a clinical trial he has enjoyed a deep and lasting remission which has enabled him to be a pioneer in providing authoritative medical information online for other people facing serious illness. As a passionate patient-advocate, and with support from many of America's leading medical centers, Andrew has hosted and helped produce several thousand webcasts and videos for patients who have cancer or a wide range of chronic and acute medical concerns.

In 2005, Andrew left HealthTalk to found Patient Power LLC, first as a weekly radio show for patients and soon thereafter as a growing website and producer of syndicated medical talk shows nationwide. Andrew hosts nearly every program. Many of the nation's leading medical centers have supported Patient Power either financially or by donating medical experts time for programs. Increasingly medical products companies, with no strings attached, have approached Andrew to support his efforts at patient empowerment.

In 2009, Andrew joined with like-minded patient advocates to form the non-profit Patient Empowerment Network.

Andrew is also the author of The Web-Savvy Patient: An Insider's Guide to Navigating the Internet When Facing Medical Crisis, published in the spring of 2011. In the book, Andrew shares the real-life success stories of powerful patients to help individuals feel confident using the Internet to find reliable medical information, connect with others, and use what they learn in effectiveconversations with their doctors.  Find out more at www.WebSavvyPatient.com.

Omar Ali

Omar Ali

Visiting Lecturer University of Portsmouth & Former Adviser, Adoption & Impact Panel, NICE

Read more

Qualified with a hospital pharmacy background, Omar has been working as the Formulary Advisor for Surrey & Sussex Healthcare NHS Trust for over 15 years, sitting on the regional Joint Drugs & Therapeutics Committee as well as the CCG/Commissioning Prescribing Clinical Network.

Omar has been a visiting Lecturer at UCLH Pharmacy Programme and was both Lecturer & Examiner on the Independent Prescribing V300 Course at the University of Surrey and has over 30 publications to date. He has been appointed as Visiting Lecturer on Value Based Pricing & Innovative Contracting at the University of Portsmouth, is an Editorial Content Adviser to Guidelines, and has recently been invited to the position of Associate Editor to the Canadian Journal of Population Therapeutics & Clinical Pharmacology.

Omar has served a position on the External Reference Group on Cost Impact Modelling for NICE for 6 years and was subsequently appointed Panel Member for the newly formed Adoption & Impact Program Reference for NICE. He advises foreign investors (US Embassy) on ‘Value Based Assessments (hosted by the UK Department of Trade & Industry) and recently delivered a Healthcare NHS Reform program to over 40 Healthcare Insurance Provider delegates visiting from the US.

Last year he was invited to address the Italian Healthcare Senate [Senato della Repubblica] on Pharmaco-economic Evaluation & Sustainability Models of Healthcare and featured at the Westminster Health Forum Keynote Seminars [chaired by Lord Howe, All Party Parliamentary Group on Pharmacy] on the Future for Pharmacy Commissioning, Organisation & Delivery. At this current time he has embarked on a PhD with his doctorate thesis entitled “Value Based Pricing & Outcomes Based, Innovative Contracting of New Medicines”.

Michael Reff

Michael Reff

Founder/Executive Director, National Community Oncology Dispensing Association, Inc. (NCODA)

Read more

Michael is employed at Hematology/Oncology Associates of Central New York where he established The Patient Rx Center, a physician dispensing platform (PDP) focused on positive patient experiences with specialty medications. He has delivered numerous presentations on the PDP and authored several articles. He is the founder and Executive Director of the National Community Oncology Dispensing Association, Inc. a patient-focused organization dedicated to proactively help shape the community oncology value proposition with regard to in-office dispensing. Michael serves on Association of Community Cancer Centers' Editorial Board, and served on their Government Affairs Committee, National RCC Advisory Committee, and Dispensing Pharmacy Project Committee. He has extensive pharmaceutical industry experience spanning many disciplines.

Purchase the Post-Conference Materials

Event Presentations • Event Audio • On Demand Subscription

Yen Nguyen

Yen Nguyen

Director of Pharmacy, Oncology Consultants

Read more

Yen obtained a BS from Texas A&M University in College Station and her PharmD from the University of Texas in Austin. Yen has extensive background in PBMs, hospital pharmacy, mail-order, and retail pharmacy experience. As pharmacy manager at Kroger pharmacy, she was awarded 3 years in a row as the fastest growth in pharmacy sales for the Southwest Region of over 140 stores. She then followed her original career path of oncology by joining as Director of Pharmacy to Oncology Consultants, PA, the largest independent physician private practice in Houston. Texas with 14 physicians and 9 clinical sites. Since joining 10 years ago, she created and now manage 2 specialty pharmacies. For the last 5 years, Oncology Consultant Pharmacy has been the top producing pharmacy of the Oncology Circle Organization from across the country. She previously was one of the original Advisory Member and speaker for Specialty Oncology Network for ION and currently serves on the Executive Board and Digital Strategist for NCODA, National Community Oncology Dispensing Association. Yen has extensive knowledge on GPOs, payor contracts, credentialing, pharmacy process, pathways, etc. Due to the extensive experience, she is a currently a referral source for difficult cases though out Texas with oral oncolytic access.

Ann Collins

Ann Collins

SVP of Strategy, Cota Healthcare

Read more

Ann Collins is Senior Vice President, Strategy for Life Sciences and Pharma at Cota, whose technology platform helps clinical, operational and financial teams use real-world evidence with a goal of empowering oncology providers with data to deliver value-based precision medicine. At the heart of Cota’s capability is the patented Cota Nodal Address (CNA) system- a digital classification methodology that precisely categorizes patient factors, their diseases and intended therapies.

Ann’s passion and track record is in cancer clinical development for industry- from smaller biotech, with leadership roles at Vion and Agios to big pharma (Schering Plough). Trained as an oncology physician associate, Ann practiced in the community and academic setting prior to joining industry.

Keith Ruark

Keith Ruark

Executive Director of Strategy Consulting, INC Research

Read more

Keith has 20+ years’ experience in the healthcare industry. He was one of the founders of AVOS Consulting before it was acquired, and has overseen the integration of this unit into Global Consulting at INC Research

  • Currently, Keith leads the Commercial & Medical Strategy global practice within INC Strategy Consulting and advises biopharma, medical device and diagnostics clients in strategy development and the critical link to execution
  • Specific life sciences commercialization experience and areas of interest:
    • Commercialization strategy ranging from innovation in the form of either new healthcare technologies or business models through to life cycle management strategies that extend through the complete life cycle of the asset
    • R&D analytics used to drive strategic and operational decision-making
  • Prior to founding AVOS and bringing this consulting business into INC Research, Keith held senior management positions within Quintiles Transnational including positions in its investment arm, PharmaBio Development (spun out now as Novaquest) and in the commercial business, Innovex; in this capacity, Keith led or had material involvement in the structuring, negotiation and evaluation of over $650m in product-based and company investments
  • Earlier in his career, Keith was a senior consultant for The Wilkerson Group, a leading health care consultancy firm acquired by IBM and served in commercial / business development and R&D positions at Roche and Procter and Gamble (P&G)
  • Keith holds a B.S. (Mechanical Engineering) from Purdue University and an MBA (Finance & Strategy) from Yale University
Sriram Shankar

Sriram Shankar

Senior Consultant, INC Strategy Consulting

Read more

Dr. Sri Shankar is a Senior Consultant with nearly 20 experience in the healthcare and life sciences industry, including the past decade spent leading concept-to-commercialization efforts of various platform technologies in individualized/precision medicine, molecular diagnostics, and medical devices. Prior to joining INC Research, he was Director of Business Development, leading financing and launch preparation efforts at a start-up cancer diagnostic device firm. In his current role, he has been involved in a variety of Pharma and Biotech commercial and medical strategy projects relevant to innovation strategy, launch development, payer strategy, and pricing, reimbursement, & market access, in US and W. European markets.

Jayson S. Slotnik

Jayson S. Slotnik

Principal and founding member, Health Policy Strategies, Inc.

Read more

Jayson S. Slotnik is a Principal and founding member of Health Policy Strategies, Inc., a Washington, D.C. based consulting firm representing innovative biotech, pharmaceutical, device, and diagnostic companies.

Jayson specializes in, and counsels clients on, the impact that Medicare and Medicaid coverage, payment, reimbursement, coding, and government policies have on commercial success. He also has experience as a healthcare strategist with demonstrated success in developing and implementing both pre- and post-launch strategies as well as life cycle management tools for pharmaceutical, biotechnology, diagnostic, and device manufacturers.

Prior to establishing Health Policy Strategies, Inc., Jayson served as the Vice President of Reimbursement and Innovation Strategies for United BioSource Corporation (UBC). There, he was responsible for developing technology-related marketing and sales strategies for current internal and new external customers in the branded specialty pharmaceutical space. Jayson partnered with the business development team to market technology strategies to over 20 branded specialty manufacturers. In addition, he maintained his policy practice, which helped distinguish UBC’s market access technology as well as affording his clients the ability to have the business drive the policy and not the reverse.

Before joining UBC, Jayson practiced law at two prominent Washington, D.C. law firms where he counseled clients on many complex health care regulatory and legal issues related to coverage, coding and reimbursement. Before returning to private practice, Jayson served as in the initial Director of Medicare Reimbursement and Economic Policy at the Biotechnology Industry Organization (BIO), the industry’s leading advocacy group. Jayson served as the liaison between BIO and Congress, CMS, and other federal agencies to implement market access policies that stimulate and reward innovation while maintaining appropriate patient access to cutting edge therapies.

Jayson serves on the editorial boards for Value-Based Cancer Care and Specialty Pharmacy Times. He speaks regularly at various healthcare reform and market access conferences.

Jayson received a Bachelor of Arts degree in English from the University of Rochester, his Master in Public Health with a concentration in Epidemiology and Biostatistics from George Washington University, and his Juris Doctor degree in Health Law from the University of Maryland School of Law.

For more information please visit: www.linkedin.com/pub/jayson-slotnik/5/230/393/

Purchase the Post-Conference Materials

Event Presentations • Event Audio • On Demand Subscription